Research site

San Juan 5402DIL

1 studies enrolling now · 13 studies all time

What they study most

Active Cutaneous Lupus Erythematosus, Acute Coronary Syndrome, Advanced or Metastatic Non-Small Cell Lung Cancer, Breast Cancer, Early Breast Cancer, Cardiovascular Disease, Lupus Erythematosus, Systemic, Lupus Nephritis, Multiple Sclerosis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis-associated Interstitial Lung Disease

Studies at this site

• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy — Recruiting now
• A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event — Recruiting now
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) — Recruiting now
• Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis — Running, not enrolling
• Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus — Running, not enrolling
• A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy — Running, not enrolling
• Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) — Completed
• Dimethyl Fumarate (DMF) Observational Study — Completed
• Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS — Completed
• Abituzumab in SSc-ILD — Stopped early
• BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis — Stopped early
• Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE) — Completed
• Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist — Completed